Firefighters for the Wrong Type of Inflammation in Tumors

Area of Science:

• Immunology
• Oncology
• Pharmacology

Background:

• Prostaglandin E2 (PGE2) is implicated in promoting tumor growth and immune suppression.
• Current immunotherapies like anti-PD-1 checkpoint inhibitors show variable efficacy.
• Modulating the tumor microenvironment is crucial for enhancing anti-cancer immune responses.

Purpose of the Study:

• To investigate the synergistic potential of inhibiting prostaglandin E2 (PGE2) with anti-PD-1 immunotherapy.
• To evaluate the impact of PGE2 inhibition on the intratumoral immune response.
• To assess this combined therapeutic strategy in preclinical cancer models and human tumor explants.

Main Methods:

• Utilized mouse models of cancer.
• Administered inhibitors of PGE2 synthesis or EP2/EP4 receptor antagonists.
• Combined these agents with anti-PD-1 immunotherapy.
• Analyzed intratumoral immune cell infiltration and cytokine production (IFNγ) in tumor explants.

Main Results:

• Inhibition of PGE2 synthesis or signaling synergized effectively with anti-PD-1 therapy.
• This combination therapy induced a robust intratumoral interferon-gamma (IFNγ) response.
• The observed effects were validated in both mouse models and fresh human tumor samples.

Conclusions:

• Targeting PGE2 pathways represents a promising strategy to enhance the efficacy of anti-PD-1 immunotherapy.
• Quenching pro-tumor inflammation via PGE2 inhibition can potentiate anti-tumor immunity.
• This approach warrants further clinical investigation for cancer treatment.